<DOC>
	<DOC>NCT00996580</DOC>
	<brief_summary>This is an open-label, single-treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-103. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Sexually active at risk for pregnancy Agreement to use study OC therapy as their only method of birth control during the study history of regular spontaneous menstrual cycles or withdrawal bleeding episodes Others as dictated by FDAapproved protocol Any contraindication to the use of oral contraceptives Pregnancy or plans to become pregnant in the next 14 months Smoker and age â‰¥ 35 years Others as dictated by FDAapproved protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Oral contraceptives</keyword>
</DOC>